Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Healthtrust
Queensland Health
Mallinckrodt
Federal Trade Commission
Chubb
Baxter
Fish and Richardson

Generated: September 20, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUVOXAMINE MALEATE

« Back to Dashboard

Clinical Trials for Fluvoxamine Maleate

Trial ID Title Status Sponsor Phase Summary
NCT00352768 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated Solvay Pharmaceuticals Phase 4 This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder
NCT00353028 Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents Completed Solvay Pharmaceuticals Phase 4 This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state
NCT01933919 A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed Meiji Seika Pharma Co., Ltd. Phase 3 The objective in 1st phase of this randomized study is to evaluate the efficacy of SME3110 compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item for children from baseline to the last observation visit in pediatric/adolescent Obsessive Compulsive Disorder subjects in short-term (10 weeks) in double blind period. The safety of SME3110 compared to placebo is also evaluated. The objective in 2nd phase of the study is to evaluate the long-term safety and efficacy of SME3110 in pediatric/adolescent Obsessive Compulsive Disorder subjects.
NCT01933919 A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed AbbVie Phase 3 The objective in 1st phase of this randomized study is to evaluate the efficacy of SME3110 compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale 10-item for children from baseline to the last observation visit in pediatric/adolescent Obsessive Compulsive Disorder subjects in short-term (10 weeks) in double blind period. The safety of SME3110 compared to placebo is also evaluated. The objective in 2nd phase of the study is to evaluate the long-term safety and efficacy of SME3110 in pediatric/adolescent Obsessive Compulsive Disorder subjects.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Fluvoxamine Maleate

Condition Name

Condition Name for Fluvoxamine Maleate
Intervention Trials
Obsessive Compulsive Disorder 3
Metastatic Cancer 1
Major Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fluvoxamine Maleate
Intervention Trials
Compulsive Personality Disorder 3
Compulsive Behavior 3
Obsessive-Compulsive Disorder 3
Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fluvoxamine Maleate

Trials by Country

Trials by Country for Fluvoxamine Maleate
Location Trials
Japan 3
China 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fluvoxamine Maleate

Clinical Trial Phase

Clinical Trial Phase for Fluvoxamine Maleate
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fluvoxamine Maleate
Clinical Trial Phase Trials
Completed 3
Terminated 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fluvoxamine Maleate

Sponsor Name

Sponsor Name for Fluvoxamine Maleate
Sponsor Trials
Solvay Pharmaceuticals 2
Haining Health-Coming Biotech Co., Ltd. 1
Guangdong General Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fluvoxamine Maleate
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
US Army
Johnson and Johnson
Daiichi Sankyo
Accenture
Mallinckrodt
UBS
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.